The CIR’s experience conducting clinical trials with malaria vaccine candidates is notable, including the:
- R32Ns1 sporozoite vaccine
- P. falciparum CSP non-repeating vaccine antigen (NS81RLF) in MPL/CWS adjuvant
- P. falciparum CSP non-repeating vaccine antigen (NS81RLF) in liposomal adjuvant
- Pvs25H, a transmission-blocking vaccine for P. vivax
- AMA1-C1/Alhydrogel with and without CPG7909, an asexual blood-stage vaccine for P. falciparum
- PpPfs25/ISA51, a transmission-blocking vaccine for P. falciparum
- ScPvs25/ISA, a transmission-blocking vaccine for P. vivax
- MSP142-C1/Alhydrogel with and without CPG7909, an asexual blood-stage vaccine for P. falciparum
Here is a link to a list of selected publications by CIR faculty about malaria.
|
| |
